Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25637783 | 0.81 | EGLN1 (0.42) | KDM4EMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL25056360 | 0.77 | MAOA (0.37) | KDM4EPOLBGAA | |
| SCHEMBL25056305 | 0.70 | PLK1 (0.46) | KDM4EALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL25056302 | 0.69 | TGFBR1 (0.35) | POLBGAACYP3A4 | |
| SCHEMBL25056298 | 0.69 | CYP11B1 (0.33) | KDM4EMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL10172668 | 0.68 | KDM4E (0.53) | KDM4EMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL17389516 | 0.68 | KDM4E (0.55) | KDM4EMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL30418927 | 0.68 | KDM4E (0.55) | KDM4EMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL25637781 | 0.67 | EGLN1 (0.41) | KDM4EMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL12855318 | 0.67 | KDM4E (0.63) | KDM4EMAPK1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | KDM4E 3796/4885MAPK1 235/4885ALDH1A1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.